title: Cumulative meta-analysis of therapeutic trials for myocardial infarction.
abstract: BACKGROUND
  The large volume of published randomized, controlled trials has led to a need for meta-analyses to track therapeutic advances. Performing a new meta-analysis whenever the results of a new trial of a particular therapy are published permits the study of trends in efficacy and makes it possible to determine when a new treatment appears to be significantly effective or deleterious. We describe the use of such a procedure, cumulative meta-analysis, to assess therapeutic trials among patients with myocardial infarction.
  
  
  METHODS
  We performed cumulative meta-analyses of clinical trials that evaluated 15 treatments and preventive measures for acute myocardial infarction.
  
  
  RESULTS
  An example of this method is its application to the use of intravenous streptokinase as thrombolytic therapy for acute infarction. Thirty-three trials evaluating this therapy were performed between 1959 and 1988. We found that a consistent, statistically significant reduction in total mortality (odds ratios, 0.74; 95 percent confidence interval, 0.59 to 0.92) was achieved in 1973, after only eight trials involving 2432 patients had been completed. The results of the 25 subsequent trials, which enrolled an additional 34,542 patients through 1988, had little or no effect on the odds ratio establishing efficacy, but simply narrowed the 95 percent confidence interval. In particular, two very large trials, the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico trial in 1986 (11,712 patients) and the Second International Study of Infarct Survival trial in 1988 (17,187 patients) did not modify the already established evidence of efficacy. We used a similar approach to study the accumulating evidence of efficacy (or lack of efficacy) of 14 other therapies and preventive measures for myocardial infarction.
  
  
  CONCLUSIONS
  Cumulative meta-analysis of therapeutic trials facilitates the determination of clinical efficacy and harm and may be helpful in tracking trials, planning future trials, and making clinical recommendations for therapy.
authors.affiliation: Department of Veterans Affairs Medical Center, Boston, MA.
authors.forename: J
authors.initials: J
authors.lastname: Lau
authors.forename: E M
authors.initials: EM
authors.lastname: Antman
authors.forename: J
authors.initials: J
authors.lastname: Jimenez-Silva
authors.forename: B
authors.initials: B
authors.lastname: Kupelnick
authors.forename: F
authors.initials: F
authors.lastname: Mosteller
authors.forename: T C
authors.initials: TC
authors.lastname: Chalmers
mesh_terms: D016001:Confidence Intervals; D006801:Humans; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000188:drug therapy / Q000628:therapy*; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D013300:Streptokinase / Q000627:therapeutic use; D015912:Thrombolytic Therapy
chemical_list: D013300:Streptokinase